Trials / Completed
CompletedNCT04369430
Study Assessing Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 110 (actual)
- Sponsor
- Alkahest, Inc. · Industry
- Sex
- All
- Age
- 50 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy and safety of AKST4290 in subjects with Parkinson's Disease who are currently on stable dopaminergic treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AKST4290 | Oral AKST4290 |
| DRUG | Placebo | Oral Placebo |
Timeline
- Start date
- 2020-01-16
- Primary completion
- 2021-02-11
- Completion
- 2021-03-10
- First posted
- 2020-04-30
- Last updated
- 2022-10-10
- Results posted
- 2022-10-10
Locations
22 sites across 5 countries: United States, Estonia, Germany, Poland, Slovakia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04369430. Inclusion in this directory is not an endorsement.